Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Public ClinicalTrials.gov record NCT05500508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
Study identification
- NCT ID
- NCT05500508
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 15 participants
Conditions and interventions
Conditions
- Cancer
- Solid Tumor
- Solid Carcinoma
- Advanced Cancer
- DIPG Brain Tumor
- Ovary Cancer
- Breast Cancer
- Papillary Thyroid Cancer
- Head and Neck Cancer
- Gastric Cancer
- Nsclc
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Esophageal Cancer
- Diffuse Midline Glioma, H3 K27M-Mutant
- Endometrial Cancer
- Cervical Cancer
- Melanoma
- Colorectal Cancer
- Glioma, Malignant
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2022 (Actual)
- Primary completion
- Dec 12, 2024 (Actual)
- Completion
- Dec 12, 2024 (Actual)
- Last update posted
- Dec 24, 2024
2022 – 2024
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Arizona | Phoenix | Arizona | 85054 | — |
| Mayo Clinic - Florida | Jacksonville | Florida | 32224 | — |
| Mayo Clinic - Minnesota | Rochester | Minnesota | 55905 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Fred Hutch Cancer Center - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05500508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 24, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05500508 live on ClinicalTrials.gov.